Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01014962 | A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus | PHASE1 | COMPLETED | 24 | — | — | Aug 24, 2009 | Dec 4, 2009 | Jun 20, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Albaconazole 400 mg cohort 1 | EXPERIMENTAL | Albaconazole 400 mg |
| Placebo cohort 1 | PLACEBO_COMPARATOR | Placebo once daily |
| Albaconozole 400 mg cohort 2 | EXPERIMENTAL | Albaconozole 400 mg every 12 hours |
| Placebo cohort 2 | PLACEBO_COMPARATOR | Placebo every 12 hours |
| Albaconozole 400 mg cohort 3 | EXPERIMENTAL | Albaconozole 400 mg every 8 hours |
| Placebo cohort 3 | PLACEBO_COMPARATOR | Placebo every 8 hours |
| Name | Type | Description |
|---|---|---|
| Albaconozole | DRUG | Albaconozole 400 mg oral once daily for 5 days |
| Placebo | DRUG | Placebo oral once daily for 5 days |
Inclusion Criteria: * Male or female subjects age 18 to 45 * A body mass index (BMI) between 18.5 and 30 kg/m2. * Good physical and mental health. * Vital signs .within the acceptable range. * Electrocardiogram (12-lead) after at least 5 minutes in supine position considered as normal or with findi...